RT Journal Article
SR Electronic
T1 A Generalized Evolutionary Classifier (EC) for Evolutionarily Guided Precision Medicine (EGPM)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.24.20201111
DO 10.1101/2020.09.24.20201111
A1 Matthew McCoy
A1 Chen-Hsiang Yeang
A1 Jin Young Yang
A1 Deepak Parashar
A1 Robert A. Beckman
YR 2020
UL http://medrxiv.org/content/early/2020/09/25/2020.09.24.20201111.abstract
AB Precision medicine (PM) matches patients to therapies, utilizing traditional biomarker classifiers. Dynamic precision medicine (DPM) is an evolutionarily directed approach which adapts every six weeks, plans ahead for future resistance development, incorporates multiple therapeutic agents, and may improve survival (simulated hazard ratio DPM:PM, HR-DPM/PM, 0.52). We developed an evolutionary classifier (EC) to select patients who benefit from DPM. Subclonal prevalence and growth, mutation, and drug sensitivity parameters determine each DPM recommended adaptation (move). In simulations, if the first two moves are identical for DPM and PM, patients will not benefit (90% negative predictive value). The first two moves provide nearly the benefit of 40 moves. Patients benefiting equally between 2 and 40 moves have extraordinary predicted benefit (HR-DPM/PM 0.04). This EC development paradigm may apply to other dynamic cancer models despite different underlying assumptions. It may reduce the duration and frequency of required monitoring, and also enable “window” clinical trials.STATEMENT OF SIGNIFICANCE Biomarker classifiers match patients to therapies. Dynamic precision medicine (DPM) directs therapeutic sequence and timing using evolutionary dynamics. We present an evolutionary classifier (EC) for predicting patient benefit from DPM, discovering that many require only briefly, thereby improving cost-effectiveness. This approach may generalize to other evolutionarily directed strategies.Competing Interest StatementRAB consults for or has recently consulted for AstraZeneca, CStone, EMD Serono, Vertex, and Zymeworks. He is the Chief Scientific Officer of Onco-Mind. The other authors declare no competing interests.Funding StatementSupported in part by The Royal Society International Exchanges Award to DP and RAB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Theoretical/Computational Study, no real patients were used, and no IRB was necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data from the study is derived from computational simulations, the methods for their generation and recreation are provided in Beckman et. al., PNAS (2012) https://doi.org/10.1073/pnas.1203559109